Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Retained Earnings (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Retained Earnings data on record, last reported at -$121.0 million in Q4 2025.

  • For Q4 2025, Retained Earnings fell 94212.89% year-over-year to -$121.0 million; the TTM value through Dec 2025 reached -$121.0 million, down 94212.89%, while the annual FY2025 figure was $128569.0, 0.0% changed from the prior year.
  • Retained Earnings reached -$121.0 million in Q4 2025 per INM's latest filing, down from $128569.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $128569.0 in Q2 2023 and bottomed at -$121.0 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$47.8 million, with a median of -$38.8 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: surged 100.14% in 2023, then plummeted 94212.89% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$82.1 million in 2021, then decreased by 20.65% to -$99.1 million in 2022, then skyrocketed by 100.13% to $128569.0 in 2023, then changed by 0.0% to $128569.0 in 2024, then tumbled by 94212.89% to -$121.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$121.0 million in Q4 2025, $128569.0 in Q3 2025, and $128569.0 in Q2 2025.